About
Our Science
News & Media
Careers
Contact Us
Urinary Cancer Test
JP
/
EN
About
Vision, Mission, and Values
Message from the CEO
Corporate Overview
Leadership Team
Company Name & Logo
Access / Location
Our Science
Cancer Detection
SMA/SCID
Bio-AI
Clinical Studies
Publications
News & Media
All
Press
Research
Media
Award
News
Careers
Contact Us
News & Media
→
All
Press
→
Research
→
Media
→
Award
→
News
Press
Press
Craif Raises $33M to Accelerate Introduction of Its Urine-Based Cancer Test to the U.S.
Series D, Co-led by Granite-Integral and Diagnostics Maker Tauns, Funds a Prospective Pancreatic Cancer Study and Expansion of U.S. Clinical Team Under New Chief Medical Officer Nick Bevins
2026.08.18
Press
Craif Refreshes Brand Identity as It Enters Its Next Phase of Global Expansion
2026.04.24
Press
Craif Opens Bio-AI Laboratory in San Diego, U.S.
2026.04.24
Press
Craif Appoints Takeo Mukai as CFO Through Local U.S. Hire ~ Driving Non-Linear Growth of Craif's Global Business with Extensive Experience Leading Exits as CEO/COO/CFO Across Multiple U.S. Healthcare Companies ~
2026.04.24
Press
Craif's Urine-Based Cancer Risk Test miSignal Is Now in More Than 2,000 Medical Institutions in Japan
2026.02.20
Press
miSignal Urine Cancer Risk Test Now Sold in More Than 4,000 Drugstores and Pharmacies in Japan
2025.12.05
Press
Craif Bio-AI Summit 2025: Company Targets Japanese Approval in 2027 and US Medicare Reimbursement in 2028
2025.11.11
Press
Craif Establishes U.S. Business Office in San Diego – Selected to Join Johnson & Johnson’s JLABS San Diego –
2025.10.16
Press
Craif Raises US＄22 million in Series C Funding, Accelerates U.S. Expansion and R&D
2025.04.28
Press
Craif Appoints Keisuke Honda, Founder of the 15.4 Billion Yen X&KSK Fund, as an Outside Director
2025.02.06
1
2
3
4
Last
News & Media
→
All
Press
→
Research
→
Media
→
Award
→
News
